- Home
- KZR vs KALA Comparison
KZR vs KALA Comparison
Compare KZR & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- KALA
- Stock Information
- Founded
- KZR 2015
- KALA 2009
- Country
- KZR United States
- KALA United States
- Employees
- KZR N/A
- KALA N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- KZR Health Care
- KALA Health Care
- Exchange
- KZR Nasdaq
- KALA Nasdaq
- Market Cap
- KZR 29.7M
- KALA 26.2M
- IPO Year
- KZR 2018
- KALA 2017
- Fundamental
- Price
- KZR $4.01
- KALA $7.38
- Analyst Decision
- KZR Hold
- KALA Strong Buy
- Analyst Count
- KZR 2
- KALA 3
- Target Price
- KZR $9.00
- KALA $14.00
- AVG Volume (30 Days)
- KZR 81.6K
- KALA 185.4K
- Earning Date
- KZR 08-19-2025
- KALA 08-08-2025
- Dividend Yield
- KZR N/A
- KALA N/A
- EPS Growth
- KZR N/A
- KALA N/A
- EPS
- KZR N/A
- KALA N/A
- Revenue
- KZR N/A
- KALA N/A
- Revenue This Year
- KZR N/A
- KALA N/A
- Revenue Next Year
- KZR N/A
- KALA N/A
- P/E Ratio
- KZR N/A
- KALA N/A
- Revenue Growth
- KZR N/A
- KALA N/A
- 52 Week Low
- KZR $3.62
- KALA $2.92
- 52 Week High
- KZR $9.18
- KALA $11.20
- Technical
- Relative Strength Index (RSI)
- KZR 38.90
- KALA 58.18
- Support Level
- KZR $3.98
- KALA $7.00
- Resistance Level
- KZR $4.23
- KALA $7.95
- Average True Range (ATR)
- KZR 0.19
- KALA 0.94
- MACD
- KZR -0.04
- KALA -0.05
- Stochastic Oscillator
- KZR 9.56
- KALA 64.65
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.